Question special

As shown in this study, Olaparib has a high response rate of 87.5% (14 out of 16) among patients who have homozygous deletions and/or deleterious mutations in DNA repair genes. Given the high specificity of this PARP inhibitor for this subset of patients with DNA repair defects, as detected by NGS, could Olaparib become the front line treatment and perhaps replace other therapies such as androgen deprivation therapy, docetaxel, etc. to avoid chemical/surgical castration in the near future? With that said, NGS would need to be adopted as a routine clinical diagnostic test to rationalize the use of PARP inhibitor ahead of other traditional therapies.